SCHEMBL20053361

SCHEMBL20053361

CCC(=O)N1CC(C(C)(C)CC)C1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.50
CHRNA3 P32297 4/20 0.50
CHRNA4 P43681 4/20 0.50
CHRNB3 Q05901 2/20 0.50
CHRNA6 Q15825 2/20 0.50
CHRNB4 P30926 2/20 0.48
CHRNA7 P36544 2/20 0.48
ALDH1A1 P00352 2/20 0.38
EPHX2 P34913 3/20 0.34
LMNA P02545 2/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD11B1 P28845 1/20 0.33
BLM P54132 1/20 0.33
GAA P10253 1/20 0.32
BIRC2 Q13490 1/20 0.31
EPHX1 P07099 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20053357 0.85 CHRNB2 (0.50) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL15298466 0.83 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL20053362 0.82 SMN1; SMN2 (0.37) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL23100380 0.82 CHRNB2 (0.42) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL15492478 0.82 CHRNB2 (0.52) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL20053294 0.77 GAA (0.46) ALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL20615648 0.76 KMT2A (0.52) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL21765914 0.73 CHRNB2 (0.72) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL21765915 0.73 CHRNB2 (0.72) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL20901012 0.73 KDM4E (0.37) ALDH1A1LMNAMAPTSMN1; SMN2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10259818-B2 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors INCYTE CORPORATION (US) 2019-04-16 US disclosed
US-20190002470-A1 BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2019-01-03 US disclosed
US-9944646-B2 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors INCYTE HOLDINGS CORPORATION (US) 2018-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002470-A1 BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS PIK3CD, PIK3CA, PIK3CB CHRNB2 4080/4885CHRNA3 3396/4885CHRNA4 4031/4885
US-10259818-B2 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors PIK3CD, PIK3CA, PIK3CB CHRNB2 4080/4885CHRNA3 3396/4885CHRNA4 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.